Clinical Trial Update: Immunogenicity of Gardasil and Twinrix and the Effect of a Dose of Gardasil or Cervarix Given 42 Months Later. [Phase 3]

View source ↗

Summary

Phase 3 trial assessing immunogenicity of Gardasil and Twinrix and the effect of a subsequent Gardasil or Cervarix dose given 42 months later.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Human Papillomavirus Infection

Drugs mentioned

• Cervarix (human papillomavirus vaccine, bivalent)
• Gardasil (human papillomavirus vaccine)
• Twinrix (Hepatitis A and B vaccine, combined)

Snippet

Sponsor: Laval University | Conditions: Human Papillomavirus | Phase 3 | Status: COMPLETED